The network pharmacology analysis indicated that there were 47 potential targets of luteolin in treating NSCLC such as TP53, AKT1, EGFR, CASP3, TNF, JUN, VEGFA, MMP1, MMP9, HMOX1, MDM2, PIK3CG, BCL2L1, etc. We then constructed a PPI network to investigate the interactions among these targets. Here, HMOX1 is linked to non-small cell lung carcinoma.